Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00829166
Registration number
NCT00829166
Ethics application status
Date submitted
22/01/2009
Date registered
26/01/2009
Date last updated
31/10/2016
Titles & IDs
Public title
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Query!
Scientific title
A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Query!
Secondary ID [1]
0
0
TDM4370g
Query!
Secondary ID [2]
0
0
BO21977
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EMILIA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Trastuzumab emtansine
Treatment: Drugs - Lapatinib
Treatment: Drugs - Capecitabine
Experimental: Trastuzumab emtansine - Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
Active Comparator: Lapatinib + Capecitabine - Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
Treatment: Drugs: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Treatment: Drugs: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Treatment: Drugs: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Query!
Assessment method [1]
0
0
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
Query!
Timepoint [1]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Primary outcome [2]
0
0
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
Query!
Assessment method [2]
0
0
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [2]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Primary outcome [3]
0
0
Percentage of Participants Who Died: Second Interim Analysis
Query!
Assessment method [3]
0
0
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
Query!
Timepoint [3]
0
0
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Query!
Primary outcome [4]
0
0
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
Query!
Assessment method [4]
0
0
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
Query!
Timepoint [4]
0
0
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Query!
Primary outcome [5]
0
0
Percentage of Participants Who Died: Final Analysis
Query!
Assessment method [5]
0
0
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
Query!
Timepoint [5]
0
0
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Query!
Primary outcome [6]
0
0
Overall Survival: Final Analysis
Query!
Assessment method [6]
0
0
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
Query!
Timepoint [6]
0
0
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Query!
Primary outcome [7]
0
0
Percentage of Participants Who Were Alive at Year 1
Query!
Assessment method [7]
0
0
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Query!
Timepoint [7]
0
0
Year 1
Query!
Primary outcome [8]
0
0
Percentage of Participants Who Were Alive at Year 2
Query!
Assessment method [8]
0
0
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Query!
Timepoint [8]
0
0
Year 2
Query!
Secondary outcome [1]
0
0
Percentage of Participants With PD or Death as Assessed by the Investigator
Query!
Assessment method [1]
0
0
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
Query!
Timepoint [1]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Secondary outcome [2]
0
0
PFS as Assessed by the Investigator
Query!
Assessment method [2]
0
0
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [2]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
Query!
Assessment method [3]
0
0
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
Query!
Timepoint [3]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Secondary outcome [4]
0
0
Duration of Objective Response (DOR) as Assessed by an IRC
Query!
Assessment method [4]
0
0
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [4]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Clinical Benefit as Assessed by an IRC
Query!
Assessment method [5]
0
0
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
Query!
Timepoint [5]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Treatment Failure
Query!
Assessment method [6]
0
0
Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
Query!
Timepoint [6]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Secondary outcome [7]
0
0
Time to Treatment Failure
Query!
Assessment method [7]
0
0
Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [7]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Symptom Progression
Query!
Assessment method [8]
0
0
Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
Query!
Timepoint [8]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Secondary outcome [9]
0
0
Time to Symptom Progression
Query!
Assessment method [9]
0
0
Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [9]
0
0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Query!
Eligibility
Key inclusion criteria
- HER2 status must be prospectively, centrally tested and be HER2-positive based on
central laboratory assay results
- Histologically or cytologically confirmed invasive breast cancer
- Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or
metastatic setting must include both a taxane, alone or in combination with another
agent, and trastuzumab, alone or in combination with another agent
- Documented progression (which occur during or after most recent treatment or within 6
months after completing of adjuvant therapy) of incurable, unresectable, locally
advanced or metastatic breast cancer, defined by the investigator
- Measurable and/or nonmeasurable disease; participants with central nervous system-only
disease are excluded
- Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either
echocardiogram or multi-gated acquisition scan
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- For women of childbearing potential and men with partners of childbearing potential,
agreement to use a highly effective, non-hormonal form of contraception; contraception
use should continue for the duration of the study treatment and for at least 6 months
after the last dose of study treatment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of treatment with trastuzumab emtansine
- Prior treatment with lapatinib or capecitabine
- Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE), Version 3.0
- History of other malignancy within the last 5 years, except for appropriately treated
carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer,
synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a
similar curative outcome as those mentioned above
- History of receiving any anti-cancer drug/biologic or investigational treatment within
21 days prior to randomization except hormone therapy, which could be given up to 7
days prior to randomization; recovery of treatment-related toxicity consistent with
other eligibility criteria
- History of radiation therapy within 14 days of randomization
- Brain metastases that are untreated, symptomatic, or require therapy to control
symptoms, as well as any history of radiation, surgery, or other therapy, including
steroids, to control symptoms from brain metastases within 2 months (60 days) of
randomization
- History of symptomatic congestive heart failure or serious cardiac arrhythmia
requiring treatment
- History of myocardial infarction or unstable angina within 6 months of randomization
- Current dyspnea at rest due to complications of advanced malignancy or current
requirement for continuous oxygen therapy
- Current severe, uncontrolled systemic disease (for example, clinically significant
cardiovascular, pulmonary, or metabolic disease)
- Pregnancy or lactation
- Current known active infection with human immunodeficiency virus (HIV), hepatitis B
virus, or hepatitis C virus
- Presence of conditions that could affect gastrointestinal absorption: Malabsorption
syndrome, resection of the small bowel or stomach, and ulcerative colitis
- History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
- Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase
deficiency
- Current treatment with sorivudine or its chemically related analogs, such as brivudine
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
991
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maine
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Maryland
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Massachusetts
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Michigan
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Minnesota
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Missouri
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Montana
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nebraska
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Nevada
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Jersey
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Mexico
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New York
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
North Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Ohio
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Oregon
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Pennsylvania
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Rhode Island
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
South Carolina
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Tennessee
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Texas
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Virginia
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Washington
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Wisconsin
Query!
Country [37]
0
0
Bosnia and Herzegovina
Query!
State/province [37]
0
0
Banja Luka
Query!
Country [38]
0
0
Bosnia and Herzegovina
Query!
State/province [38]
0
0
Sarajewo
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Belo Horizonte
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Curitiba
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Goiania
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Itajai
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
JAU
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
Joao Pessoa
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Porto Alegre - Rs
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Porto Alegre
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Rio de Janeiro
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Santo Andre
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
Sao Paulo
Query!
Country [50]
0
0
Bulgaria
Query!
State/province [50]
0
0
Plovdiv
Query!
Country [51]
0
0
Bulgaria
Query!
State/province [51]
0
0
Sofia
Query!
Country [52]
0
0
Bulgaria
Query!
State/province [52]
0
0
Varna
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Alberta
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
British Columbia
Query!
Country [55]
0
0
Canada
Query!
State/province [55]
0
0
Nova Scotia
Query!
Country [56]
0
0
Canada
Query!
State/province [56]
0
0
Ontario
Query!
Country [57]
0
0
Canada
Query!
State/province [57]
0
0
Quebec
Query!
Country [58]
0
0
Colombia
Query!
State/province [58]
0
0
Bogota
Query!
Country [59]
0
0
Colombia
Query!
State/province [59]
0
0
Monteria
Query!
Country [60]
0
0
Denmark
Query!
State/province [60]
0
0
Herlev
Query!
Country [61]
0
0
Denmark
Query!
State/province [61]
0
0
København
Query!
Country [62]
0
0
Denmark
Query!
State/province [62]
0
0
Odense
Query!
Country [63]
0
0
Finland
Query!
State/province [63]
0
0
Helsinki
Query!
Country [64]
0
0
Finland
Query!
State/province [64]
0
0
Tampere
Query!
Country [65]
0
0
Finland
Query!
State/province [65]
0
0
Turku
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Avignon
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Bordeaux
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Brest
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Caen
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Dijon
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
La Roche Sur Yon
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Montpellier
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Paris
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Saint Brieuc
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Saint Herblain
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Vandoeuvre-les-nancy
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Aschaffenburg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Berlin
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Bonn
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Dortmund
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Freiburg
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Fuerstenwalde
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Hamburg
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Karlsruhe
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Kiel
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Offenbach
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Stralsund
Query!
Country [88]
0
0
Hong Kong
Query!
State/province [88]
0
0
Hong Kong
Query!
Country [89]
0
0
India
Query!
State/province [89]
0
0
Bangalore
Query!
Country [90]
0
0
India
Query!
State/province [90]
0
0
Gurgaon
Query!
Country [91]
0
0
India
Query!
State/province [91]
0
0
Kolkata
Query!
Country [92]
0
0
India
Query!
State/province [92]
0
0
New Delhi
Query!
Country [93]
0
0
India
Query!
State/province [93]
0
0
Pune
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Aviano
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Bologna
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Candiolo
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Genova
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Meldola
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Milano
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Napoli
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Negrar
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Pisa
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Reggio Emilia
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Roma
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Rozzano
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Sassari
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Terni
Query!
Country [108]
0
0
Korea, Republic of
Query!
State/province [108]
0
0
Kyunggi-do
Query!
Country [109]
0
0
Korea, Republic of
Query!
State/province [109]
0
0
Seoul
Query!
Country [110]
0
0
Mexico
Query!
State/province [110]
0
0
Acapulco
Query!
Country [111]
0
0
Mexico
Query!
State/province [111]
0
0
Oaxaca
Query!
Country [112]
0
0
Mexico
Query!
State/province [112]
0
0
Toluca
Query!
Country [113]
0
0
New Zealand
Query!
State/province [113]
0
0
Newtown
Query!
Country [114]
0
0
New Zealand
Query!
State/province [114]
0
0
Palmerston North
Query!
Country [115]
0
0
Philippines
Query!
State/province [115]
0
0
Diliman, Quezon City
Query!
Country [116]
0
0
Philippines
Query!
State/province [116]
0
0
Quezon City, Luzon
Query!
Country [117]
0
0
Poland
Query!
State/province [117]
0
0
Bialystok
Query!
Country [118]
0
0
Poland
Query!
State/province [118]
0
0
Gdansk
Query!
Country [119]
0
0
Poland
Query!
State/province [119]
0
0
Krakow
Query!
Country [120]
0
0
Poland
Query!
State/province [120]
0
0
Lublin
Query!
Country [121]
0
0
Poland
Query!
State/province [121]
0
0
Opole
Query!
Country [122]
0
0
Poland
Query!
State/province [122]
0
0
Poznan
Query!
Country [123]
0
0
Poland
Query!
State/province [123]
0
0
Warszawa
Query!
Country [124]
0
0
Portugal
Query!
State/province [124]
0
0
Coimbra
Query!
Country [125]
0
0
Portugal
Query!
State/province [125]
0
0
Lisboa
Query!
Country [126]
0
0
Portugal
Query!
State/province [126]
0
0
Porto
Query!
Country [127]
0
0
Russian Federation
Query!
State/province [127]
0
0
Kemerovo
Query!
Country [128]
0
0
Russian Federation
Query!
State/province [128]
0
0
Moscow
Query!
Country [129]
0
0
Russian Federation
Query!
State/province [129]
0
0
St Petersburg
Query!
Country [130]
0
0
Singapore
Query!
State/province [130]
0
0
Singapore
Query!
Country [131]
0
0
Slovenia
Query!
State/province [131]
0
0
Ljubljana
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Barcelona
Query!
Country [133]
0
0
Spain
Query!
State/province [133]
0
0
Córdoba
Query!
Country [134]
0
0
Spain
Query!
State/province [134]
0
0
Lerida
Query!
Country [135]
0
0
Spain
Query!
State/province [135]
0
0
Madrid
Query!
Country [136]
0
0
Spain
Query!
State/province [136]
0
0
Santander
Query!
Country [137]
0
0
Spain
Query!
State/province [137]
0
0
Sevilla
Query!
Country [138]
0
0
Spain
Query!
State/province [138]
0
0
Valencia
Query!
Country [139]
0
0
Spain
Query!
State/province [139]
0
0
Zaragoza
Query!
Country [140]
0
0
Sweden
Query!
State/province [140]
0
0
Eskilstuna
Query!
Country [141]
0
0
Sweden
Query!
State/province [141]
0
0
Gaelve
Query!
Country [142]
0
0
Sweden
Query!
State/province [142]
0
0
Goteborg
Query!
Country [143]
0
0
Switzerland
Query!
State/province [143]
0
0
Luzern
Query!
Country [144]
0
0
Switzerland
Query!
State/province [144]
0
0
St. Gallen
Query!
Country [145]
0
0
Taiwan
Query!
State/province [145]
0
0
Kaohsung
Query!
Country [146]
0
0
Taiwan
Query!
State/province [146]
0
0
Taichung
Query!
Country [147]
0
0
Taiwan
Query!
State/province [147]
0
0
Taipei
Query!
Country [148]
0
0
Taiwan
Query!
State/province [148]
0
0
Taoyuan
Query!
Country [149]
0
0
United Kingdom
Query!
State/province [149]
0
0
Bournemouth
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Cardiff
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
Denbigh
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
London
Query!
Country [153]
0
0
United Kingdom
Query!
State/province [153]
0
0
Manchester
Query!
Country [154]
0
0
United Kingdom
Query!
State/province [154]
0
0
New Castle Upon Tyne
Query!
Country [155]
0
0
United Kingdom
Query!
State/province [155]
0
0
Northwood
Query!
Country [156]
0
0
United Kingdom
Query!
State/province [156]
0
0
Poole
Query!
Country [157]
0
0
United Kingdom
Query!
State/province [157]
0
0
Preston
Query!
Country [158]
0
0
United Kingdom
Query!
State/province [158]
0
0
Romford
Query!
Country [159]
0
0
United Kingdom
Query!
State/province [159]
0
0
Sutton
Query!
Country [160]
0
0
United Kingdom
Query!
State/province [160]
0
0
Weston Super Mare
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial
designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of
capecitabine + lapatinib in participants with human epidermal growth factor receptor 2
(HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated
until disease progression (PD), unmanageable toxicity, or study termination. Once disease
progression is reported, all participants will be followed for survival every 3 months until
death, loss to follow-up, withdrawal of consent, or study termination.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00829166
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Genentech, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00829166
Download to PDF